Related Experiment Video
Updated: May 1, 2026
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Combination treatment with theranostic nanoparticles for glioblastoma sensitization to TMZ
Byunghee Yoo1, Marytheresa A Ifediba, Subrata Ghosh
1Molecular Imaging Laboratory, MGH/HST Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Building 75, 13th Street, Charlestown, MA, 02129, USA.
Purpose:
Tumor resistance to chemotherapeutic drugs is one of the major obstacles in the treatment of glioblastoma multiforme (GBM). In this study, we attempted to modulate tumor response to chemotherapy by combination treatment that included experimental (small interference RNA (siRNA), chlorotoxin) and conventional (temozolomide, TMZ) therapeutics.
Procedures:
siRNA therapy was used to silence O(6)-methylguanine methyltransferase (MGMT), a key factor in brain tumor resistance to TMZ. For targeting of tumor cells, we used chlorotoxin (CTX), a peptide with antitumoral properties. siRNA and CTX were conjugated to iron oxide nanoparticles (NP) that served as the drug carrier and allowed the means to monitor the changes in tumor volume by magnetic resonance imaging (MRI).
Results:
Theranostic nanoparticles (termed CTX-NP-siMGMT) were internalized by T98G glioblastoma cells in vitro leading to enhancement of TMZ toxicity. Combination treatment of mice bearing orthotopic tumors with CTX-NP-siMGMT and TMZ led to significant retardation of tumor growth, which was monitored by MRI.
Conclusions:
While our results demonstrate that siRNA delivery by targeted nanoparticles resulted in modulating tumor response to chemotherapy in GBM, they also point to a significant contribution of CTX to tumor cell death.
Insights
Targeted nanoparticles delivering small interference RNA (siRNA) combined with chlorotoxin (CTX) and temozolomide (TMZ) effectively enhanced glioblastoma treatment. This theranostic approach significantly slowed tumor growth in vivo.
Area of Science:
- Neuro-oncology
- Nanomedicine
- Molecular therapy
Background:
- Glioblastoma multiforme (GBM) exhibits significant resistance to chemotherapy, hindering effective treatment.
- O(6)-methylguanine methyltransferase (MGMT) is a key enzyme contributing to temozolomide (TMZ) resistance in brain tumors.
Purpose of the Study:
- To modulate glioblastoma response to chemotherapy using a combination of experimental therapeutics and conventional drugs.
- To develop a theranostic nanoparticle system for targeted delivery of small interference RNA (siRNA) and chlorotoxin (CTX).
Main Methods:
- siRNA was used to silence MGMT, a target for overcoming TMZ resistance.
- Chlorotoxin (CTX), an antitumoral peptide, was conjugated to iron oxide nanoparticles (NP) along with siRNA (CTX-NP-siMGMT).
- Magnetic resonance imaging (MRI) was employed to monitor tumor volume changes.
Main Results:
- CTX-NP-siMGMT nanoparticles were internalized by T98G glioblastoma cells, increasing sensitivity to TMZ in vitro.
- Combination treatment with CTX-NP-siMGMT and TMZ significantly retarded orthotopic tumor growth in mice, as confirmed by MRI.
Conclusions:
- Targeted nanoparticle-mediated siRNA delivery effectively modulated chemotherapy response in GBM.
- Chlorotoxin (CTX) demonstrated a significant contribution to tumor cell death in the combination therapy.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy